FDA Pipeline preview, October 2008 (vernakalant, doripenem, custirsen, droxidopa, amrubicin, dronedarone, imatinib)

Gavreto used to treat metastatic RET fusion-positive non-small cell lung cancer and RET fusion-positive thyroid cancer.

This week’s approval expands Seldardsi indications to treat adults with Crohn’s disease and ulcerative colitis.

Zolbetuximab — now with the brand name Vyloy — is a monoclonal antibody to treat patients with advanced gastric and gastroesophageal cancers.

David Joyner has been appointed president and CEO of CVS Health effective immediately.

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Hympavzi is the first anti-tissue factor pathway inhibitor approved in the United States for hemophilia.